(1) Due to the patient’s refusal and being uncooperative at some point in time during the treatment process, we lacked PD-L1 expression levels in tumor tissues, although we likewise found evidence in the peripheral blood that the patient could benefit from PD-1 inhibitors; (2) We did not detect changes in immune function in the peripheral blood after PDT combined with targeted therapy and immunotherapy. This evidence concerns the gene CD274 and neoplasm.